Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,515.33
(
0.95%
)
US TECH 100
28,864.80
(
0.97%
)
Dow Jones
50,144.85
(
0.91%
)
Brent Oil
102.50
(
-1.15%
)
Bitcoin
81,519.52
(
2.82%
)
News Focus
News Focus
Post# of 257560
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

marthambles

Send PM Follow Ignore
Followers 9
Posts 1369
Boards Moderated 0
Alias Born 04/26/2004

marthambles

Re: DewDiligence post# 202006

Monday, 12/19/2016 11:16:37 AM

Monday, December 19, 2016 11:16:37 AM

Post# of 257560
RVNC - if Xeomin is non-inferior to Botox, why hasn't an acquirer emerged? Why hasn't the commercial opportunity been recognized by a pharmaceutical firm with the capability to properly market it and make it a worthy competitor? Given the size of the market, it would seem like a slam dunk.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today